Global Oncology Academy

Treating Steroid-Refractory Chronic GVHD: How to Transition to Second-Line Therapy

ReachMD Healthcare Image

Here’s how you can modify treatment approaches for patients with steroid-refractory chronic graft versus host disease.

  • Overview

    Did you know that only about a third of patients with chronic graft versus host disease (GVHD) will have a durable response to steroids? Learn how you can better manage patients with steroid-refractory chronic GVHD with this expert panel featuring Dr. Ned Waller, Director of the Regenerative Medicine Program at the Winship Cancer Institute of Emory University, and Dr. George Chen, Associate Professor of Stem Cell Transplantation at the MD Anderson Cancer Center in Houston.

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free